Here our work was highlighted in an article entitled: Boosting hepatic NAD⁺ prevents and reverses NAFLD in mice, published in Nature Reviews Gastroenterology & Hepatology.

“Few therapies are approved for the treatment of NAFLD. Now, researchers have shown that treatment with nicotinamide riboside, a precursor for NAD+ biosynthesis, can protect mice against the development of diet-induced NAFLD by increasing hepatic NAD+ levels.”